ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:RCUS • US03969F1093
21.685 USD
+0.64 (+3.07%)
Last: Feb 2, 2026, 03:45 PM
Overall RCUS gets a fundamental rating of 2 out of 10. We evaluated RCUS against 524 industry peers in the Biotechnology industry. Both the profitability and financial health of RCUS have multiple concerns. RCUS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- RCUS had negative earnings in the past year.
- RCUS had a negative operating cash flow in the past year.
- RCUS had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: RCUS reported negative operating cash flow in multiple years.
1.2 Ratios
- RCUS's Return On Assets of -35.01% is fine compared to the rest of the industry. RCUS outperforms 62.40% of its industry peers.
- Looking at the Return On Equity, with a value of -78.21%, RCUS is in line with its industry, outperforming 53.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.01% | ||
| ROE | -78.21% | ||
| ROIC | N/A |
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for RCUS has been increased compared to 1 year ago.
- RCUS has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for RCUS is higher compared to a year ago.
2.2 Solvency
- RCUS has an Altman-Z score of 0.96. This is a bad value and indicates that RCUS is not financially healthy and even has some risk of bankruptcy.
- With a decent Altman-Z score value of 0.96, RCUS is doing good in the industry, outperforming 64.12% of the companies in the same industry.
- RCUS has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
- RCUS's Debt to Equity ratio of 0.22 is on the low side compared to the rest of the industry. RCUS is outperformed by 65.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.96 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
- RCUS has a Current Ratio of 3.65. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of RCUS (3.65) is comparable to the rest of the industry.
- RCUS has a Quick Ratio of 3.65. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of RCUS (3.65) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
- The earnings per share for RCUS have decreased by -9.21% in the last year.
- Looking at the last year, RCUS shows a decrease in Revenue. The Revenue has decreased by -8.75% in the last year.
- The Revenue has been growing by 76.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-9.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27%
Revenue 1Y (TTM)-8.75%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-45.83%
3.2 Future
- RCUS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.69% yearly.
- The Revenue is expected to grow by 17.77% on average over the next years. This is quite good.
EPS Next Y-12.81%
EPS Next 2Y-13.79%
EPS Next 3Y-4.48%
EPS Next 5Y13.69%
Revenue Next Year-5.59%
Revenue Next 2Y-32.13%
Revenue Next 3Y-17.95%
Revenue Next 5Y17.77%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RCUS. In the last year negative earnings were reported.
- Also next year RCUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as RCUS's earnings are expected to decrease with -4.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.79%
EPS Next 3Y-4.48%
5. Dividend
5.1 Amount
- RCUS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ARCUS BIOSCIENCES INC / RCUS FAQ
What is the ChartMill fundamental rating of ARCUS BIOSCIENCES INC (RCUS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RCUS.
What is the valuation status for RCUS stock?
ChartMill assigns a valuation rating of 0 / 10 to ARCUS BIOSCIENCES INC (RCUS). This can be considered as Overvalued.
What is the profitability of RCUS stock?
ARCUS BIOSCIENCES INC (RCUS) has a profitability rating of 1 / 10.
What is the earnings growth outlook for ARCUS BIOSCIENCES INC?
The Earnings per Share (EPS) of ARCUS BIOSCIENCES INC (RCUS) is expected to decline by -12.81% in the next year.